NEW YORK--(BUSINESS WIRE)--Kallyope, Inc., a clinical stage biotechnology company discovering and developing novel, oral small-molecule therapeutics for diseases with high unmet need, today announced that it has received $8.2 million from the Bill & Melinda Gates Foundation. In collaboration with other institutions affiliated with the foundation, Kallyope will use its unique gut-focused screening and validation capabilities to identify promising bioactive compounds for improving maternal, newborn, and children’s health in the epicenters of the global food and nutrition crisis.
The four-year agreement focuses on discovery and characterization of metabolites that can be developed and delivered to undernourished pregnant and lactating women who are experiencing environmental enteric dysfunctions (EED). EED is an incompletely defined syndrome of inflammation, high enteropathogen burden, reduced absorptive capacity, and reduced barrier function of the small intestine. It is widespread in low and middle-income countries.
“This is a unique, inspiring opportunity for Kallyope to positively impact global health by leveraging our industry-leading research platform, Klarity™, which integrates multiple sophisticated technologies to develop transformative therapeutics in the areas of metabolism, gastrointestinal disease, and neurological disorders,” said Jay Galeota, president and CEO, Kallyope. “We are honored to receive support from the Gates Foundation to make progress towards giving every person, everywhere, the chance to lead a healthy, productive life. We are especially energized to focus on health advancements for pregnant women and new mothers and to prevent disease early in the lives of children.”
According to a report issued in March by UNICEF, the number of pregnant and breastfeeding adolescent girls and women suffering from acute malnutrition has soared since 2020, with South Asia and Sub-Saharan Africa hit hardest. Childhood EED has been associated with stunting (low height-for-age), with devastating, long-term consequences for child health and development. Globally, 51 million children under 2 years are stunted due to malnutrition; of those, about half become stunted during pregnancy and the first six months of life. Stunting peaks at 3 months of age and is difficult to reverse after 2 years of age. Fetal growth restriction is predictive of stunting up to 2 years of age, and therefore early intervention with mothers during pregnancy can be a potential mechanism to improve infant outcomes later in life.
Under the agreement, the foundation will provide a grant to Kallyope of $8.2 million over four years. Kallyope will retain rights to develop compounds derived from the identified agents as possible therapeutics in other global regions, including as supplements in low-resource nations.
About Kallyope
Kallyope, a clinical stage biotechnology company, is leveraging its proprietary Klarity™ therapeutic platform to discover and develop novel, oral small-molecule therapeutics in areas with high unmet medical need, including diabetes and obesity, gastrointestinal disease, and neurological disorders.
